Sigrid V. Carlsson, MD, PhD, MPH

DKFZ German Cancer Research Center

Heidelberg, Germany

Sigrid V. Carlsson, MD, PhD, MPH, is the Division Head of the Clinical Epidemiology of Early Cancer Detection at DKFZ German Cancer Research Center in Heidelberg, Germany. Her research focuses on developing risk-stratified approaches to screening, diagnosis, treatment, and follow-up.

Dr. Carlsson earned her MD and PhD from Gothenburg University in Sweden. She earned an MPH from Harvard in Boston, Massachusetts. Dr. Carlsson has been funded by the Prevent Cancer Foundation to develop a decision support tool for prostate cancer screening. She holds a career development award from the National Institutes of Health/National Cancer Institute, mentored by Drs. Jennifer Hay and Jada Hamilton, to optimize the practical application of shared decision-making and implementing risk-stratified approaches to screening and follow-up in oncology.

Dr. Carlsson serves on the National Comprehensive Cancer Network (NCCN) and is a panel member for the American Urological Association (AUA) guidelines for early detection of prostate cancer. She has authored and co-authored over 300 publications and has been featured in Société Internationale d’Urologie Journal, The Journal of Urology, European Urology, Clinical Chemistry, Urologic Oncology Seminars and Original Investigations, and more.

Talks by Sigrid V. Carlsson, MD, PhD, MPH

How to Optimize the Use of Prostate-specific Antigen in the Current Era

Sigrid V. Carlsson, MD, PhD, MPH | May 2019

Sigrid V. Carlsson, MD, PhD, MPH, suggests that, rather than abandoning PSA screening altogether, doctors should focus on patient selection for screening. She provides 5 key considerations for PSA screening, emphasizing risk-stratification and shared decision-making.

Prostate Cancer Active Surveillance in 2019

Sigrid V. Carlsson, MD, PhD, MPH | Apr 2019

Sigrid V. Carlsson, MD, PhD, MPH, reviews recent guidelines regarding patient selection and protocols for prostate cancer active surveillance. She provides methods for counseling patients who would benefit from active surveillance, but experience anxiety from the prospect of foregoing aggressive therapy.

Prostate Cancer and Early Detection: Should We Follow the NCCN Guidelines?

Sigrid V. Carlsson, MD, PhD, MPH | Feb 2019

Sigrid V. Carlsson, MD, PhD, MPH, compares the National Comprehensive Cancer Network (NCCN) Prostate Cancer Early Detection v2.2018 guidelines to Memorial Sloan Kettering Cancer Center (MSKCC) recommendations for prostate cancer screening in terms of optimizing oncological benefits and reducing negative effects on quality of life.

The USPSTF Prostate Cancer Screening Recommendation: A Swinging Pendulum

Sigrid V. Carlsson, MD, PhD, MPH | Jan 2019

Sigrid V. Carlsson, MD, PhD, MPH, reviews the history of PSA screening, from its discovery to the controversy related to United States Preventive Services Task Force (USPSTF) gradings during the current era. She also assesses the harms and benefits of PSA screening and responsible application of the PSA test.

Shared Decision Making for Prostate Cancer Decisions: When the Patient has a Laundry List and the Doctor has 8 Minutes

Sigrid V. Carlsson, MD, PhD, MPH | Jan 2019

Sigrid V. Carlsson, MD, PhD, MPH discusses the psychology, history, and practical application of shared decision making. She then provides recommendations for clinicians counseling patients deciding whether or not to undergo PSA screening and if they should go on active surveillance.